Study Seeking Patients with Schizophrenia

  • STATUS
    Recruiting
  • sponsor
    TEVA
Send
Updated on 25 March 2021
See if I qualify

Summary

Study Seeking Patients with Schizophrenia

Description

A Randomized, Open-label, Multiple-dose, Parallel Design, Comparative Bioequivalence Study of Paliperidone Palmitate Extended-Release Injectable Suspension (156 mg/1.0 mL) Versus Invega Sustenna® (paliperidone palmitate) Extended-Release Injectable Suspension (156mg/1.0 mL) in Schizophrenia Patients Already Stabilized on Paliperidone Palmitate

Details
Condition Schizophrenia and Schizoaffective Disorders, Mental Disability, Psychosis
Clinical Study IdentifierTX148352
SponsorTEVA
Last Modified on25 March 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Males and females 18-65 years of age
Body mass index of 18.0-38.0 kg/m2 inclusive
Patients must not have been either hospitalized for worsening of schizophrenic symptoms or judged by the investigator as having significant exacerbation of schizophrenic symptoms during the 3 months prior to screening
Patients must have an identified support person
Patients must have a stable place of residence for the 3 months prior to screening

Exclusion Criteria

Have a known hypersensitivity to paliperidone, risperidone, or to any excipients in the Formulation
Patients with a history of or who are currently diagnosed as having epilepsy or convulsion Disorders
Patients who have a history of malignancy within the past five years except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Positive serology for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV)
Current heavy smoking, defined as smoking > 2 packs of cigarettes (or 5 cigars) per day for 1 year or greater
Patients who have received an investigational drug as part of a clinical trial within 30 days prior to screening or current participation in another clinical trial
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note